Delineation of a FOXA1/ERα/AGR2 regulatory loop that is dysregulated in endocrine therapy-resistant breast cancer

Tricia M. Wright, Suzanne E. Wardell, Jeff S. Jasper, James P. Stice, Rachid Safi, Erik R. Nelson, Donald P. McDonnell

Research output: Contribution to journalArticle

Abstract

Tamoxifen, a selective estrogen receptor (ER) modulator (SERM), remains a frontline clinical therapy for patients with ERα-positive breast cancer. However, the relatively rapid development of resistance to this drug in the metastatic setting remains an impediment to a durable response. Although drug resistance likely arises by many different mechanisms, the consensus is that most of the implicated pathways facilitate the outgrowth of a subpopulation of cancer cells that can either recognize tamoxifen as an agonist or bypass the regulatory control of ERα. Notable in this regard is the observation here and in other studies that expression of anterior gradient homology 2 (AGR2), a known proto-oncogene and disulfide isomerase, was induced by both estrogen (17β-estradiol, E2) and 4-hydroxytamoxifen (4OHT) in breast cancer cells. The importance of AGR2 expression is highlighted here by the observation that (i) its knockdown inhibited the growth of both tamoxifen-sensitive and -resistant breast cancer cells and (ii) its increased expression enhanced the growth of ERα- positive tumors in vivo and increased the migratory capacity of breast cancer cells in vitro . Interestingly, as with most ERα target genes, the expression of AGR2 in all breast cancer cells examined requires the transcription factor FOXA1. However, in tamoxifen-resistant cells, the expression of AGR2 occurs in a constitutive manner, requiring FOXA1, but loses its dependence on ER. Taken together, these data de fine the importance of AGR2 in breast cancer cell growth and highlight a mechanism where changes in FOXA1 activity obviate the need for ER in the regulation of this gene.

Original languageEnglish (US)
Pages (from-to)1829-1839
Number of pages11
JournalMolecular Cancer Research
Volume12
Issue number12
DOIs
StatePublished - Dec 1 2014

Fingerprint

Estrogen Receptors
Breast Neoplasms
Tamoxifen
Selective Estrogen Receptor Modulators
Drug Resistance
Therapeutics
Growth
Protein Disulfide-Isomerases
Proto-Oncogenes
Estradiol
Neoplasms
Estrogens
Transcription Factors
Observation
Gene Expression
Genes

ASJC Scopus subject areas

  • Molecular Biology
  • Oncology
  • Cancer Research

Cite this

Delineation of a FOXA1/ERα/AGR2 regulatory loop that is dysregulated in endocrine therapy-resistant breast cancer. / Wright, Tricia M.; Wardell, Suzanne E.; Jasper, Jeff S.; Stice, James P.; Safi, Rachid; Nelson, Erik R.; McDonnell, Donald P.

In: Molecular Cancer Research, Vol. 12, No. 12, 01.12.2014, p. 1829-1839.

Research output: Contribution to journalArticle

Wright, Tricia M. ; Wardell, Suzanne E. ; Jasper, Jeff S. ; Stice, James P. ; Safi, Rachid ; Nelson, Erik R. ; McDonnell, Donald P. / Delineation of a FOXA1/ERα/AGR2 regulatory loop that is dysregulated in endocrine therapy-resistant breast cancer. In: Molecular Cancer Research. 2014 ; Vol. 12, No. 12. pp. 1829-1839.
@article{4b991e3fd8de4d1f829408fa24c3a3ff,
title = "Delineation of a FOXA1/ERα/AGR2 regulatory loop that is dysregulated in endocrine therapy-resistant breast cancer",
abstract = "Tamoxifen, a selective estrogen receptor (ER) modulator (SERM), remains a frontline clinical therapy for patients with ERα-positive breast cancer. However, the relatively rapid development of resistance to this drug in the metastatic setting remains an impediment to a durable response. Although drug resistance likely arises by many different mechanisms, the consensus is that most of the implicated pathways facilitate the outgrowth of a subpopulation of cancer cells that can either recognize tamoxifen as an agonist or bypass the regulatory control of ERα. Notable in this regard is the observation here and in other studies that expression of anterior gradient homology 2 (AGR2), a known proto-oncogene and disulfide isomerase, was induced by both estrogen (17β-estradiol, E2) and 4-hydroxytamoxifen (4OHT) in breast cancer cells. The importance of AGR2 expression is highlighted here by the observation that (i) its knockdown inhibited the growth of both tamoxifen-sensitive and -resistant breast cancer cells and (ii) its increased expression enhanced the growth of ERα- positive tumors in vivo and increased the migratory capacity of breast cancer cells in vitro . Interestingly, as with most ERα target genes, the expression of AGR2 in all breast cancer cells examined requires the transcription factor FOXA1. However, in tamoxifen-resistant cells, the expression of AGR2 occurs in a constitutive manner, requiring FOXA1, but loses its dependence on ER. Taken together, these data de fine the importance of AGR2 in breast cancer cell growth and highlight a mechanism where changes in FOXA1 activity obviate the need for ER in the regulation of this gene.",
author = "Wright, {Tricia M.} and Wardell, {Suzanne E.} and Jasper, {Jeff S.} and Stice, {James P.} and Rachid Safi and Nelson, {Erik R.} and McDonnell, {Donald P.}",
year = "2014",
month = "12",
day = "1",
doi = "10.1158/1541-7786.MCR-14-0195",
language = "English (US)",
volume = "12",
pages = "1829--1839",
journal = "Molecular Cancer Research",
issn = "1541-7786",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Delineation of a FOXA1/ERα/AGR2 regulatory loop that is dysregulated in endocrine therapy-resistant breast cancer

AU - Wright, Tricia M.

AU - Wardell, Suzanne E.

AU - Jasper, Jeff S.

AU - Stice, James P.

AU - Safi, Rachid

AU - Nelson, Erik R.

AU - McDonnell, Donald P.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Tamoxifen, a selective estrogen receptor (ER) modulator (SERM), remains a frontline clinical therapy for patients with ERα-positive breast cancer. However, the relatively rapid development of resistance to this drug in the metastatic setting remains an impediment to a durable response. Although drug resistance likely arises by many different mechanisms, the consensus is that most of the implicated pathways facilitate the outgrowth of a subpopulation of cancer cells that can either recognize tamoxifen as an agonist or bypass the regulatory control of ERα. Notable in this regard is the observation here and in other studies that expression of anterior gradient homology 2 (AGR2), a known proto-oncogene and disulfide isomerase, was induced by both estrogen (17β-estradiol, E2) and 4-hydroxytamoxifen (4OHT) in breast cancer cells. The importance of AGR2 expression is highlighted here by the observation that (i) its knockdown inhibited the growth of both tamoxifen-sensitive and -resistant breast cancer cells and (ii) its increased expression enhanced the growth of ERα- positive tumors in vivo and increased the migratory capacity of breast cancer cells in vitro . Interestingly, as with most ERα target genes, the expression of AGR2 in all breast cancer cells examined requires the transcription factor FOXA1. However, in tamoxifen-resistant cells, the expression of AGR2 occurs in a constitutive manner, requiring FOXA1, but loses its dependence on ER. Taken together, these data de fine the importance of AGR2 in breast cancer cell growth and highlight a mechanism where changes in FOXA1 activity obviate the need for ER in the regulation of this gene.

AB - Tamoxifen, a selective estrogen receptor (ER) modulator (SERM), remains a frontline clinical therapy for patients with ERα-positive breast cancer. However, the relatively rapid development of resistance to this drug in the metastatic setting remains an impediment to a durable response. Although drug resistance likely arises by many different mechanisms, the consensus is that most of the implicated pathways facilitate the outgrowth of a subpopulation of cancer cells that can either recognize tamoxifen as an agonist or bypass the regulatory control of ERα. Notable in this regard is the observation here and in other studies that expression of anterior gradient homology 2 (AGR2), a known proto-oncogene and disulfide isomerase, was induced by both estrogen (17β-estradiol, E2) and 4-hydroxytamoxifen (4OHT) in breast cancer cells. The importance of AGR2 expression is highlighted here by the observation that (i) its knockdown inhibited the growth of both tamoxifen-sensitive and -resistant breast cancer cells and (ii) its increased expression enhanced the growth of ERα- positive tumors in vivo and increased the migratory capacity of breast cancer cells in vitro . Interestingly, as with most ERα target genes, the expression of AGR2 in all breast cancer cells examined requires the transcription factor FOXA1. However, in tamoxifen-resistant cells, the expression of AGR2 occurs in a constitutive manner, requiring FOXA1, but loses its dependence on ER. Taken together, these data de fine the importance of AGR2 in breast cancer cell growth and highlight a mechanism where changes in FOXA1 activity obviate the need for ER in the regulation of this gene.

UR - http://www.scopus.com/inward/record.url?scp=84919335730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919335730&partnerID=8YFLogxK

U2 - 10.1158/1541-7786.MCR-14-0195

DO - 10.1158/1541-7786.MCR-14-0195

M3 - Article

C2 - 25100862

AN - SCOPUS:84919335730

VL - 12

SP - 1829

EP - 1839

JO - Molecular Cancer Research

JF - Molecular Cancer Research

SN - 1541-7786

IS - 12

ER -